Prevention of Trinitrobenzene Sulfonic Acid-Induced Experimental Colitis by Oral Administration of a Poly(lactic-coglycolic Acid) Microsphere Containing Prostaglandin E2 Receptor Subtype 4 Agonist
Authors:
- Shinji UemotoSUShinji Uemoto
- Yasuhiko TabataYTYasuhiko Tabata
Open Access
- 1 May 2012
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 341 (2) , 340-349
Abstract
Prostaglandin E2 receptor subtype 4 (EP4) agonists are known to reduce intestinal inflammation and enhance epithelium regeneration. We explored the possibility of colonic delivery of an EP4 agonist, 2-[(4-{[2-((1R,2R,3R)-3-hydroxy-2-{(1E,3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl}-5-oxocyclopentyl)ethyl]sulfanyl}butanoyl)oxy]ethyl nonanoate (ONO-AE2-724), using poly(lactic-coglycolic acid) (PLGA) microspheres. Colitis was induced in mice by the intrarectal administration of trinitrobenzene sulfonic acid (TNBS). ONO-AE2-724-PLGA microspheres (EP4-MS) were prepared by the standard technique. Drug distributions after oral administration of EP4-MS were determined by liquid chromatography-tandem mass spectrometry analysis. To evaluate the protective effect of EP4-MS, animals were orally treated by gavage with single doses of EP4-MS 24 h before TNBS instillation. The changes in body weight, histopathology, immunohistochemistry, and expression of inflammatory cytokines were evaluated. Oral administration of EP4-MS enhanced colonic tissue drug concentration without any increase in the serum concentration during the 48 h after intake. EP4-MS pretreatment, but not unloaded ONO-AE2-724, significantly attenuated TNBS-induced colitis and diminished colonic mRNA expression levels of proinflammatory cytokines. In addition, a significant increase in the expression of CD25 and FoxP3 was found in isolated lamina propria CD4+ T cells of EP4-MS-treated mice. Immunohistochemical analysis of Ki-67 and single-stranded DNA revealed that EP4-MS pretreatment significantly suppressed apoptosis of colonic cells and promoted epithelial cell proliferation. These results suggest that EP4-MS protect mice from TNBS-induced colitis by intestinal local ONO-AE2-724 delivery. The EP4-MS may offer a promising new therapeutic strategy to treat inflammatory bowel diseases.Keywords
This publication has 32 references indexed in Scilit:
- Pharmacological intervention studies using mouse models of the inflammatory bowel diseasesInflammatory Bowel Diseases, 2011
- Comparison of Prostaglandin E2 Receptor Subtype 4 Agonist and Sulfasalazine in Mouse Colitis Prevention and TreatmentThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Effects of 15d‐PGJ2‐loaded poly(D,L‐lactide‐co‐glycolide) nanocapsules on inflammationBritish Journal of Pharmacology, 2010
- Clinical Pharmacology of 5-ASA Compounds in Inflammatory Bowel DiseaseGastroenterology Clinics of North America, 2010
- Dual roles of PGE 2 -EP4 signaling in mouse experimental autoimmune encephalomyelitisProceedings of the National Academy of Sciences, 2010
- The Prevention of Colitis by E Prostanoid Receptor 4 Agonist through Enhancement of Epithelium Survival and RegenerationThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Prostaglandin E2receptor distribution and function in the gastrointestinal tractBritish Journal of Pharmacology, 2006
- Prostaglandin E2 EP4 receptor–selective agonist facilitates sternal healing after harvesting bilateral internal thoracic arteries in diabetic ratsThe Journal of Thoracic and Cardiovascular Surgery, 2006
- The Immunology of Mucosal Models of InflammationAnnual Review of Immunology, 2002
- PROSTAGLANDIAN BIOLOGY IN INFLAMMATORY BOWEL DISEASEGastroenterology Clinics of North America, 2001